Akanda (AKAN) Receivables - Accured (2024 - 2025)
Akanda (AKAN) posted quarterly Receivables - Accured of $92638.0 for Q4 2025, up 1337.14% year-over-year from $6446.0 in Q4 2024, and up 143.04% quarter-over-quarter from $38116.0 in Q2 2025.
Akanda (AKAN) Receivables - Accured (2024 - 2025) Analysis & Trends
Akanda's Receivables - Accured history runs 2 years deep, the most recent figure standing at $92638.0 for Q4 2025.
- In Q4 2025, Receivables - Accured rose 1337.14% year-over-year to $92638.0; the TTM figure through Dec 2025 stood at $92638.0 (up 1337.14% YoY), while the FY2025 annual figure was $92638.0, up 1337.14% from the prior year.
- Receivables - Accured for Q4 2025 stood at $92638.0, up from $38116.0 in the prior quarter.
- The five-year high for Receivables - Accured was $92638.0 in Q4 2025, with the low at $6446.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables - Accured (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Akanda | 267,491.09 | 267,491.09 | - | 92,638.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 92,638.00 |
| Dec 31, 2025 | 92,638.00 |
| Jun 30, 2025 | 38,116.00 |
| Jun 30, 2025 | 38,116.00 |
| Dec 31, 2024 | 6,446.00 |
| Dec 31, 2024 | 6,446.00 |